Diagnostic prostate MRI can be a good tool for triaging biopsy candidates, as the one-two punch of that exam followed by MRI-guided biopsy of suspicious lesions has again proven not only clinically efficacious but also cost-effective when compared with transrectal ultrasound-guided biopsy. 

British, Swedish and South African scientists say they have produced proton computed tomography (pCT) images of sufficient clinical quality that their achievement “creates a new vision for cancer treatment” and “opens up a totally new medical imaging field,” according to the newsroom at the University of Lincoln in the U.K.

Prostate biopsy via the perineum with local anesthetic and MRI targeting is feasible, tolerable and can be performed in ambulatory settings, according to a British study published online May 9 in Prostate Cancer and Prostatic Diseases.

The 2017 Defense Appropriations Bill greenlighted by the Senate last week includes a $10 billion increase, to $90 billion, for the Pentagon’s prostate cancer research program.

Liver cancer may face a formidable new adversary in the form of a novel MRI contrast agent that, in preclinical experiments, has shown its ability to wring clear tumor images from both T1- and T2-weighted MRI scans.

In what they’re calling the first molecular drug-imaging study in children, Dutch researchers have shown that PET/CT can help quantify performance of the cancer drug bevacizumab (trade name Avastin) inside pediatric brain tumors. 

Want to save a kidney patient from undergoing cancer surgery he or she doesn’t really need? Add a little sestamibi SPECT/CT imaging, suggest Johns Hopkins researchers.

After assessing several decades’ worth of survey data on more than 110,000 radiologic technologists, researchers have all but ruled out a dose-response association between cumulative protracted occupational radiation and death by brain tumor.